EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies

Samarth R. Rathod, Amar M. Raval, Aastha Ukani, Jaini Patel, Ashok Kumar

Pharmacology and Toxicology Research · 13.11.2026 · 2 · 85-97

DOI: 10.68163/ptr.2026.76 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology and Toxicology Research, online erschienen am 13.11.2026. Verfasst von Samarth R. Rathod und 4 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) improve targeted drug delivery but are often associated with hematological toxicity. This review examines the structural, mechanistic and clinical evidence on ADC-induced hematological toxicity, focusing on approved ADCs and strategies for dose adjustment. Approved ADCs, including Gemtuzumab Ozogamicin (GO), Inotuzumab Ozogamicin (IO), trastuzumab emtansine, brentuximab vedotin, Polatuzumab Vedotin (PV), Sacituzumab Govitecan (SG), trastuzumab deruxtecan, Enfortumab Vedotin (EV), tisotumab vedotin, Loncastuximab Tesirine (LT), belantamab mafodotin, mirvetuximab soravtansine and disitamab vedotin, exhibit distinct hematological toxicity profiles. Common adverse events include neutropenia, thrombocytopenia, anemia, leukopenia, lymphopenia and febrile neutropenia. These toxicities are influenced by factors such as antigen distribution, linker stability, payload characteristics, drug-to-antibody ratio, Fc receptor-mediated uptake and nonspecific endocytosis. Management strategies include dose interruption or reduction, growth factor support, transfusions and regular laboratory monitoring. Hematological toxicity is an important factor affecting the tolerability of ADCs. Understanding the mechanisms underlying these toxicities is essential for improving their clinical management and guiding the development of safer next-generation ADCs.

Zitieren

APA

Rathod, S. R., Raval, A. M., Ukani, A., Patel, J., & Kumar, A. (2026). Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies. Pharmacology and Toxicology Research, 2, 85-97. https://doi.org/10.68163/ptr.2026.76

Vancouver

Rathod SR, Raval AM, Ukani A, Patel J, Kumar A. Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies. Pharmacology and Toxicology Research. 2026;2:85-97. doi:10.68163/ptr.2026.76

BibTeX
@article{Rathod2026,
  author = {Rathod, Samarth R. and Raval, Amar M. and Ukani, Aastha and Patel, Jaini and Kumar, Ashok},
  title = {Decoding Haematological Toxicity Associated with Antibody-Drug Conjugates: Mechanisms, Clinical Profiles and Management Strategies},
  journal = {Pharmacology and Toxicology Research},
  year = {2026},
  volume = {2},
  pages = {85--97},
  doi = {10.68163/ptr.2026.76}
}
Kostenlos starten →